Description: Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Home Page: www.inotivco.com
2701 Kent Avenue
West Lafayette,
IN
47906
United States
Phone:
765 463 4527
Officers
| Name | Title |
|---|---|
| Mr. Robert W. Leasure Jr. | President, CEO & Director |
| Ms. Beth A. Taylor CPA | Senior VP of Finance & CFO |
| Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. | Chief Strategy Officer & Director |
| Dr. Peter T. Kissinger | Founder, Chairman Emeritus & Scientific Advisor |
| Mr. Brennan Freeman | VP of Finance, Principal Accounting Officer & Corporate Controller |
| Ms. Andrea Castetter | SVP of General Counsel, Corporate Secretary & Chief Compliance Officer |
| Mr. Jeffrey Arthur Krupp | Chief Human Resources Officer |
| Mr. John Gregory Beattie DSA | Chief Operating Officer of DSA |
| Dr. Adrian Hardy Ph.D. | Chief Commercial Officer |
| Ms. Lizanne Muller | Group President of RMS |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6008 |
| Price-to-Sales TTM: | 0.1986 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 1955 |